Zydus Lifesciences gains after getting tentative approval from USFDA for dyskinesia drug

4 Oct 2022 , 02:50 PM

Amantadine is indicated for the treatment of dyskinesia (sudden uncontrolled movements) in patients with Parkinsons disease who are treated with levodopa therapy, with or without dopaminergic medicines. The pharmaceutical company said that the drug will be manufactured at the groups formulation manufacturing facility at Ahmedabad SEZ, India. According to IQVIA MAT August 2022 data, Amantadine Extended-Release Capsules had annual sales of $2.7 million in the United States. The group now has 325 approvals and has so far filed over 428 ANDAs since the commencement of the filing process in FY 2003-04. Zydus Lifesciences is a discovery-driven, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The companys consolidated net profit fell 11.7% to Rs 518.3 crore on a 1.8% increase in total income from operations to Rs 4,072.7 crore in Q1 FY23 over Q1 FY22. Powered by Capital Market – Live News